Orchestra BioMed Holdings Inc. (OBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Orchestra BioMed Holdings Inc. (OBIO) has a cash flow conversion efficiency ratio of -0.333x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.55 Million) by net assets ($43.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Orchestra BioMed Holdings Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Orchestra BioMed Holdings Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read OBIO current and long-term liabilities for a breakdown of total debt and financial obligations.
Orchestra BioMed Holdings Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Orchestra BioMed Holdings Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
UJU Electronics Co. Ltd
KQ:065680
|
0.027x |
|
DAEA TI Co. Ltd
KQ:045390
|
-0.059x |
|
PTC India Financial Services Limited
NSE:PFS
|
0.392x |
|
Akmerkez Gayrimenkul Yatirim Ortakligi AS
IS:AKMGY
|
0.014x |
|
Re Max Holding
NYSE:RMAX
|
-0.509x |
|
CARGO Therapeutics, Inc. Common Stock
NASDAQ:CRGX
|
-0.326x |
|
Creditwest Faktoring AS
IS:CRDFA
|
-0.586x |
|
New Era Energy & Digital, Inc.
NASDAQ:NUAI
|
-0.193x |
Annual Cash Flow Conversion Efficiency for Orchestra BioMed Holdings Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Orchestra BioMed Holdings Inc. from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see Orchestra BioMed Holdings Inc. (OBIO) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $32.96 Million | $-50.56 Million | -1.534x | -126.29% |
| 2023-12-31 | $68.04 Million | $-46.13 Million | -0.678x | -21.59% |
| 2022-12-31 | $52.53 Million | $-29.29 Million | -0.558x | -304.40% |
| 2021-12-31 | $-71.23 Million | $-19.43 Million | 0.273x | -49.43% |
| 2020-12-31 | $-48.54 Million | $-26.18 Million | 0.539x | -- |
About Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develop… Read more